miR-10b (2q31.1, intergenic) Downregulated in breast cancer. Overexpressed in metastatic breast cancer (does not predict metastasis in early stages).
Activates cell migration and extracellular matrix remodeling. Target: HOXD10.
miR-15a, miR-16-1 cluster (13q14.3, intron 4 noncoding RNA DLEU2) Downregulated in CLL, DLBCL, multiple myeloma, pituitary adenoma, prostate and pancreatic cancer. Germline mutations in B-CLL patients and in NZB mice that develop CLL-like disorder.
Induce apoptosis in leukemia cells. miR-16 regulates cell cycle by downregulating G0/G1 proteins. Targets: BCL2, CAPRIN1, CARD10, CCND1, CDK6, CDC27, CGI-38, CYCE, DMTF1, HMGA2, MCL1, MYB, NGN2, VEGF, WNT3A.
Low expression of miR-15a, miR-16 in de novo CLL (good prognosis). miR-16 modulates chemotherapy potency, sensitivity to vincristine in gastric cancer (predicts response).
Upregulated in nasopharyngeal carcinoma
Target: BRCA1 -17, miR-18a, miR-19a, miR20a, miR-19b-1, miR-17-92 cluster (13q31.3, intron 3 C13orf25) Overexpression in lung and colon cancer, lymphoma, multiple myeloma, medulloblastoma miR-17, miR-18a, miR-19a, miR-20a, miR-19b- -335, miR-206, and miR-126 are suppressors of breast cancer metastasis. The differential expression of miRNA genes in malignant compared with normal tissue can be explained by three different mechanisms: location of miRNAs in cancer-associated genomic regions, epigenetic mechanisms, and alterations in the miRNA processing or transcription machinery. The let-7 miRNA family and the miR-15a/miR-16-1 clusters are located in loci deleted in lung cancer and CLL, respectively; the miR-17-92 genomic locus is amplified in B cell lymphoma. The miRNA miR-127 is re-expressed after DNA demethylation and histone deacetylase inhibition in cancer cells; miR-124a is transcriptionally inactivated by hypermethylation of CpG islands in different tumor cell lines. Impaired miRNA processing enhances cellular transformation and tumorigenesis, as shown by the conditional deletion of Dicer1, which increases tumor development in a K-Ras-induced mouse model of lung cancer. Moreover, reduced expression of Dicer and Drosha has been observed in various human cancers. Several transcription factors regulate the expression of miRNAs, e.g., the tumor suppressor protein p53 regulates the expression of miR-34 family members, MYC is a negative regulator of miRNA expression, STAT3 regulates miR-21 expression at the transcriptional level, and Twist transactivates miR-10b transcription. The functional consequences of altered patterns of miRNA expression are just starting to be understood. Self-sustaining growth signals can be induced by miR-21 overexpression, which is responsible for PTEN repression and loss of negative regulation by AKT kinase. Insensitivity to antigrowth signals is achieved by inhibition of E2F transcription factors caused by overexpression of the miR-17-92 cluster on chromosome 13q31.1 and by overexpression of the miR-106b-25 cluster on chromosome 7q22.1. Specifically, miR-20a inhibits expression of E2F2 and E2F3, whereas miR-17-5p, miR-20a, miR-106b , and miR-92 inhibit expression of E2F1. Modulation of apoptosis may occur by direct regulation of miRNAs by proapoptotic (p53 and miR-34 family) or antiapoptotic (IL6/STAT3 and miR-21) pathways, or by direct targeting of antiapoptotic (BCL2, MCL1 proteins and the miR-15/16 cluster) or proapoptotic (TP53BP1 and miR-155) proteins. Deregulation of telomerase activity can be achieved in tumors through reduced expression of miR-138, which represses translation of TERT mRNA and induces unrestricted proliferation. Blood vessel formation (angiogenesis) is regulated by miRNAs, and hypoxia is a proven regulator of miRNA expression. The oncomiR-17-92 cluster that is regulated by MYC participates in the creation of a more aggressive, richly perfused tumor phenotype, whereas hypoxia contributes to the modulation of miRNA expression (including miR-210) partly by direct transcriptional activation of HIF-1 by specific miRNAs. Due to the specificity of targets and regulatory mechanisms, an miRNA may be an oncogene in one tumor type but a tumor suppressor in another.
miR
MicroRNA expression profiling of human tumors has identified signatures that are associated with diagnosis, prognosis, and treatment efficacy. Distinct miRNA fingerprints characterize highly aggressive cancers, e.g., overexpression of miR-155 and downregulation of let-7 miRNAs in lung cancer cells indicates a poor prognosis. Furthermore, miRNA profiling can be used to successfully classify poorly differentiated tumors, including those with an unknown primary site. For example, high expression of miR-21 is associated with poor survival and a poor therapeutic response to chemotherapy in colon cancer patients. The development of agents that block or mimic the expression and functions of miRNAs may represent a new therapeutic option for treating cancer patients.
Abbreviations AID, activated induced cytidine deaminase; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B cell lymphoma; EMT, epithelialmesenchymal transition; LOH, loss of heterozygosity; LRF, leukemia/lymphoma-related factor; NSCLC, non-small cell lung cancer; NZB, New Zealand Black; TTP, ADAM metallopeptidase with thrombospondin type I motif.
